Unisys Corporation is riding back-to-back catalysts into its next earnings in a way that leaves short sellers caught on the wrong side of a 62% one-month rally.
The story starts with Q1 numbers. Unisys beat EPS estimates by $0.17 — 17 cents ahead, against a stock that was trading below $3. The next day the stock jumped more than 20%. Then, just this week, the company announced it was selected as a technology services provider across all six lots of the UK Government Crown Commercial Service Technology Services Framework. That award landed on May 13, adding fresh fuel to a stock already trading 14% higher on the week. Against that backdrop, the SI % of Float at 8.2% looks like a squeeze that hasn't fully resolved.
Short positioning here is the defining dynamic. Shorts hold 8.2% of the free float — elevated and stubborn. The position has crept up roughly 0.5 percentage points since late April, even as the stock roared higher. That's a notable divergence. Borrow costs are modest at 0.48% APR, offering no impediment to maintaining the position. Availability has loosened considerably too: the borrow availability reading has eased dramatically from April, when it was far tighter, confirming that shorts have not been forced out by a supply squeeze. They are choosing to stay in. Options tell a different story, though. The put/call ratio has collapsed to 0.97 — more than one standard deviation below its 20-day average of 1.61 and near the low end of the 52-week range. A ratio that was running above 2.5 in late April has halved in a fortnight. Options traders have pivoted from defensive hedging to something closer to outright bullish exposure in the span of two earnings-driven weeks.
The Street has been slow to catch up. Analyst coverage is thin and the most recent actions are dated. Needham reiterated a Buy in February with a $4 target — a target the stock has not yet reached but is now closing in on at $3.24. William Blair initiated with Outperform in December; Jefferies sits at Hold. The consensus mean target of $5.00 implies roughly 54% upside from current levels, which looks coherent given the stock's trajectory. The bull case centres on a 45% year-over-year jump in contract value in Q1 2026, improving profitability, and reaffirmed full-year guidance. The bear case remains structural: non-GAAP margins guided at 8–9%, net leverage at 3.5x against a peer median of 0.8x, and revenue growth barely out of contraction. The EV/EBITDA reading of 2.0x is extremely lean, reflecting how little confidence the market had until very recently. The PE at 3.5x is similarly distressed-company territory. Factor scores add one more supporting data point: EPS surprise ranks in the 86th percentile of the universe, consistent with a company that has repeatedly beaten low expectations.
Institutional flows offer an interesting footnote. BlackRock added 222,600 shares through April 30, and Millennium Management grew its position by 878,000 shares in Q4 2025 — a meaningful accumulation for a stock of this market cap. Michael Thomson, who joined as CFO in 2026, disclosed a position of nearly 2 million shares as of early March. That same week, a cluster of insiders — including two separate CFO filings and the COO — sold small amounts at $2.43. Those sales look routine in size and price context; the stock has since rallied 33% from that level. This week, the Chief Accounting Officer sold just $24,000 worth at $3.16 — a minimal transaction that carries little signal.
The next earnings event is scheduled for June 2. With Q1 having generated a 20% single-day move and the prior quarter producing a 4% gain the following day, the setup heading into June is unusually charged. The most relevant questions by then will be whether the UK Crown Commercial Service win translates into disclosed contract value, and whether the 8.2% short position has continued to rebuild or finally begins to unwind in the face of sustained contract momentum.
See the live data behind this article on ORTEX.
Open UIS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
